The human papillomavirus vaccine: an oncology nursing issue.
In Canada, approximately 1,500 women are diagnosed with cervical cancer every year, and 581 will die of the disease (WHO/ICO Information Centre on HPV and Cervical Cancer, 2007). The importance of preventing cervical cancer is clear, as the effects that this disease has on the lives of women and their families regardless of culture, sex, nationality or country is evident. With the recent media attention and release of the Human Papillomavirus (HPV) vaccine in Canada, it is crucial that oncology nurses understand HPV, its role in the development of cervical cancer, and the HPV vaccine. A brief overview of HPV and its involvement in the development of cervical cancer will be discussed in this paper. In addition, information on the HPV vaccine and its implications, as well as the current policy for the vaccine in Canada will be addressed. It will become evident how the role of the oncology nurse, as an educator and advocate regarding the implementation of this vaccine is crucial for successful acceptance of this vaccine. Finally, future implications of the vaccine and avenues of research will be touched upon.
Buick
Catriona
C
Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario M5T 1P8. catriona.buick@utoronto.ca
Metcalfe
Kelly
K
D002170:Canada / Q000453:epidemiology; D005260:Female; D006801:Humans; D009859:Oncology Nursing; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D010353:Patient Education as Topic; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control
D053918:Papillomavirus Vaccines